Enzymotec is pleased to announce the termination of a clinical trial evaluating the effect of Sharp-PS® on well being parameters in diabetes mellitus type II patients.
Results showed that administration of Sharp-PS® for four weeks ameliorated well being parameters, including physical functioning, general health, and anxiety (p<0.05).
Importantly, a significant reduction in cortisol level (10-12%) was also observed.
This study, conducted in Russia, is part of Enzymotec's continuous efforts to expand its line of products and variety of applications.
Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional ingredients for dietary supplements, clinical nutrition and advanced infant nutrition. Key products are: Sharp-PS® line of products- phosphatidylserine based ingredients for cognitive improvement, InFat® - structured fat for infant formulas, Krill Oil+™, Crill™, and CardiaBeat®.